PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors
Feng Bai(Shanxi Medical University), Xin‐Hai Pei(Chinese Academy of Medical Sciences & Peking Union Medical College), Shiqin Liu(University of California, Los Angeles), Chuying Wang(Guilin University of Electronic Technology), Charles M. Perou(University of North Carolina at Chapel Hill), Wei‐Guo Zhu(Shenzhen University), Daniel P. Hollern(University of North Carolina at Chapel Hill), Li Fu(Shenzhen University), Xiong Liu(Xinjiang University), Lihan Zhang(Chinese Academy of Sciences), Cheng Fan(University of North Carolina at Chapel Hill), Alexandria Scott(Stowers Institute for Medical Research)
Cited by 24
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k